BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7679837)

  • 1. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens.
    Propper DJ; Woo J; Macleod AM; Catto GR; Thomson AW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):673-4. PubMed ID: 7679837
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.
    Thomson AW; Propper DJ; Woo J; Whiting PH; Milton JI; Macleod AM
    Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):355-69. PubMed ID: 7693791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose FK 506 inhibits sensitisation after blood transfusions.
    Propper DJ; Woo J; Thomson AW; Catto GR; Macleod AM
    Transplant Proc; 1990 Aug; 22(4):1649-51. PubMed ID: 1697114
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
    Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of rapamycin on humoral immunity in vivo. Suppression of primary responses but not of ongoing alloantibody synthesis or memory responses.
    Propper DJ; Woo J; Macleod AM; Catto GR; Thomson AW
    Transplantation; 1992 Dec; 54(6):1058-63. PubMed ID: 1465771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin treatment prevents and/or erases sensitization and abrogates accelerated rejection of vascularized organ allografts.
    Schmidbauer G; Hancock WW; Wasowska BA; Sablinski T; Kupiec-Weglinski JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):712-3. PubMed ID: 8438450
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
    Morris RE
    Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
    Rondeau E
    Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
    [No Abstract]   [Full Text] [Related]  

  • 9. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.
    Pelekanou V; Trezise AE; Moore AL; Kay JE
    Transplant Proc; 1991 Dec; 23(6):3200-1. PubMed ID: 1721408
    [No Abstract]   [Full Text] [Related]  

  • 10. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
    Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
    Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
    [No Abstract]   [Full Text] [Related]  

  • 11. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Nakatani T; Yamamoto K; Ohyama A; Miyao H; Kumata N; Kishimoto T
    Transplant Proc; 1994 Aug; 26(4):1913-4. PubMed ID: 7520610
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 13. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 14. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
    Hultsch T; Hohman RJ
    Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapamycin effects on immunologic reconstitution.
    Vogelsang GB; Hess AD
    Transplant Proc; 1993 Feb; 25(1 Pt 1):727-8. PubMed ID: 8438459
    [No Abstract]   [Full Text] [Related]  

  • 16. The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506.
    Nakajima H; Oka T
    Transplant Proc; 1996 Apr; 28(2):1052-5. PubMed ID: 8623224
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect.
    Cooper MH; Gregory SH; Thomson AW; Fung JJ; Starzl TE; Wing EJ
    Transplant Proc; 1991 Dec; 23(6):2957-8. PubMed ID: 1721326
    [No Abstract]   [Full Text] [Related]  

  • 18. FK 506 and rapamycin: molecular probes of T-lymphocyte activation.
    Bierer BE; Jin YJ; Fruman DA; Calvo V; Burakoff SJ
    Transplant Proc; 1991 Dec; 23(6):2850-5. PubMed ID: 1721296
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo.
    Francavilla A; Starzl TE; Carr B; Azzarone A; Carrieri G; Zeng QH; Porter KA
    Transplant Proc; 1991 Dec; 23(6):2817-20. PubMed ID: 1721287
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptides derived from alpha-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection.
    Shirwan H; Leamer M; Wang HK; Makowka L; Cramer DV
    Transplantation; 1995 Feb; 59(3):401-10. PubMed ID: 7871571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.